Nuvalent
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 Biotechnology
業務概覽 Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules thatare designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
公司地址 One Broadway, 14th Floor, Cambridge, MA, USA, 02142
電話號碼 +1 857 357-7000
傳真號碼 --
公司網頁 https://www.nuvalent.com
員工數量 228
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Henry E. Pelish Chief Scientific Officer -- 26/02/2026
Dr. Christopher D. Turner, M.D. Chief Medical Officer 美元 500.10K 26/02/2026
Ms. Alexandra Balcom, C.P.A.,M.B.A. Chief Financial Officer, Principal Accounting Officer and Treasurer 美元 457.20K 26/02/2026
Dr. Deborah Miller, J.D.,PhD Chief Legal Officer and Secretary 美元 440.50K 26/02/2026
Ms. Darlene Noci, A.C.I.S. Chief Development Officer 美元 432.70K 26/02/2026
Dr. James R. Porter, PhD Director, Chief Executive Officer and President 美元 627.00K 26/02/2026
 
董事會成員
董事會 職務 更新日期
Ms. Christy J. Oliger Independent Director 26/02/2026
Mr. Grant C. Bogle Independent Director 26/02/2026
Ms. Anna Protopapas Chairman of the board 26/02/2026
Dr. Joseph Pearlberg, M.D.,PhD Independent Director 26/02/2026
Dr. James R. Porter, PhD Director, Chief Executive Officer and President 26/02/2026
Dr. Cameron A. Wheeler, PhD Independent Director 26/02/2026
Dr. Michael L. Meyers, M.D.,PhD Independent Director 26/02/2026
Dr. Sapna Srivastava, PhD Independent Director 26/02/2026
Mr. Ron Squarer Independent Director 26/02/2026
 
所屬ETF (更新日期: 07/03/2026 03:35)
代號 名稱 佔比% ▼ 持有日期
HDGProShares Hedge Replication0.0001%27/02/2026
GTPEGoldman Sachs MSCI Wld Priv Eq RtTrkrETF0.00003%27/02/2026
BKSEBNY Mellon US Small Cap Core Equity ETF<0.000001%05/02/2026
CLSEConvergence Long/Short Equity ETF<0.000001%09/01/2026
DCORDimensional US Core Equity 1 ETF<0.000001%08/12/2025
DFACDimensional US Core Equity 2 ETF<0.000001%09/12/2025
DFAUDimensional US Core Equity Market ETF<0.000001%04/12/2025
DFSUDimensional US Sustainability Core 1 ETF<0.000001%04/12/2025
ESMLiShares ESG Aware MSCI USA Small-Cap ETF<0.000001%28/02/2026
FDIFFidelity Disruptors ETF<0.000001%02/02/2026
IWNiShares Russell 2000 Value ETF<0.000001%28/02/2026
PTLInspire 500 ETF<0.000001%01/10/2025
SBIOALPS Medical Breakthroughs ETF<0.000001%19/12/2025
SMMDiShares Russell 2500 ETF<0.000001%27/02/2026
TMEDT. Rowe Price Health Care ETF<0.000001%13/09/2025
  1    2    3   4  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.